Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563479 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
A Phase 3 study of HPV-Related Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 291
- Enrollment target
- 9
- Study locations
NCT06563479: Recruiting Phase 3 study of HPV-Related Squamous Cell Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT06563479 is a Phase 3 study of HPV-Related Squamous Cell Carcinoma that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 291 participants, above the 181-participant average among 6 other HPV-Related Squamous Cell Carcinoma trials with a reported enrollment target (61% higher). The trial reports 9 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06563479, a Phase 3 study of HPV-Related Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 291 participants
- Enrollment target
- 9
- Study locations
Study Summary
The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the following: * Whether a lower dose of radiation in combination with standard chemotherapy causes fewer side effects than the standard dose of radiation therapy in combination with standard chemotherapy * How the study approaches (lower dose of radiation therapy + standard chemotherapy and standard dose of radiation therapy + standard chemotherapy) affect participants' quality of life. The researchers will measure quality of life by having participants fill out questionnaires.
Primary Outcome
The measurement of survival will be evaluated as a time from randomization to events endpoint (i.e., death due to any cause) so that censored data are allowed. To assess the overall survival rate, Kaplan-Meier estimates will be calculated and reported.
Conditions Studied
Interventions
- OTHER Assessments
- COMBINATION_PRODUCT Chemoradiation
- DIAGNOSTIC_TEST FMISO-PET Scan
Study Locations (9)
New York
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Connecticut
- Hartford Healthcare (Data Collection Only) - Hartford
Florida
- Baptist Alliance MCI (Data Collection Only) - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
What NCT06563479 shows while recruiting
NCT06563479 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, above the 181-participant average among 6 other HPV-Related Squamous Cell Carcinoma trials with a reported enrollment target (61% higher).
The record links to 1 condition, with HPV-Related Squamous Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Assessments is the first listed.
NCT06563479 lists 9 locations in 4 states (New York, New Jersey, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06563479 about?
NCT06563479 is a clinical study titled "A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer". The researchers are doing this study to find out if a personalized approach to chemoradiation therapy (which may include a lower dose of radiation) is as effective as the standard chemoradiation therapy in people with HPV-positive throat cancer. Other purposes of this study include looking at the fo...
What is the current status of trial NCT06563479?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 291 participants. The study started on 2024-08-19. Estimated completion is 2027-08.
What conditions does trial NCT06563479 study?
This clinical trial studies the following conditions: HPV-Related Squamous Cell Carcinoma.
What interventions are being tested in trial NCT06563479?
The interventions under investigation include: Assessments (OTHER), Chemoradiation (COMBINATION_PRODUCT), FMISO-PET Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06563479?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06563479 being conducted?
This trial has 9 study locations across Connecticut, Florida, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HPV-Related Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers
RECRUITING · Phase 1
-
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
RECRUITING · Phase 2
-
Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca
RECRUITING · Phase 2
-
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma
ACTIVE NOT RECRUITING · Phase 2
-
De-Escalation Therapy for Human Papillomavirus Negative Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02074839 · 291 participants · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- NCT03769766 · 291 participants · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
- NCT05406622 · 292 participants · NA
MOTIV BTK Randomized Controlled Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI